Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada
Retrieved on:
Tuesday, September 26, 2023
Public Health Agency of Canada, COVID-19, Cohort (statistics), Calendar, Opioid use disorder, OUD, Doctor of Philosophy, UDS, Incidence, Addiction medicine, RAAM, Journal, MCFP, Patient, Risk, Injection, Methadone, AM, Journal of Addiction Medicine, Public Health Agency, Fentanyl, Pharmaceutical industry, Indivior
This study, conducted during the COVID-19 pandemic in Canada, also showed improvements in additional parameters suggestive of clinical benefit.
Key Points:
- This study, conducted during the COVID-19 pandemic in Canada, also showed improvements in additional parameters suggestive of clinical benefit.
- The percentage of individuals with urinary drug screen (UDS)-detected fentanyl use within the first month of treatment was 23% with SUBLOCADE; 22% with sublingual buprenorphine/naloxone, and 66% with methadone.
- During the six months following the initiation of treatment, UDS-detected fentanyl use decreased to 13% with SUBLOCADE, 10% with sublingual buprenorphine/naloxone, and 51% with methadone.
- "This study shows the potential positive impact of using SUBLOCADE in OUD treatment to help reduce non-fatal opioid overdoses in Canada, including from fentanyl use," said Christian Heidbreder, PhD, Chief Scientific Officer, Indivior.